An­oth­er Langer-backed biotech breaks out of stealth mode, aims for the clin­ic with hear­ing loss ther­a­py

David Lucchi­no

Over the last 18 months the team at Fre­quen­cy Ther­a­peu­tics’ Kendall Square of­fice has been mak­ing qui­et progress with its pre­clin­i­cal work on a new ap­proach to cur­ing hear­ing loss, ex­plor­ing the po­ten­tial of a ther­a­peu­tic tech­nique that emerged out of the lab of MIT’s se­r­i­al sci­ence en­tre­pre­neur Bob Langer and his col­league Jeff Karp. To­day, though, the stealthy ramp-up is over as the biotech de­buts its man­age­ment team and R&D strat­e­gy.

David Lucchi­no, the CEO, tells me that it all got start­ed years ago when Langer, who’s been work­ing in the re­gen­er­a­tive med­i­cine are­na, brought up the re­search he was do­ing on prog­en­i­tor cells.

“There are 15,000 hair cells in your ear” which are need­ed to hear prop­er­ly, says Chris Loose, co-founder and CSO. Noise and oth­er fac­tors de­stroy that in­tri­cate bi­o­log­ic ma­chin­ery need­ed for hear­ing. But the prog­en­i­tor stem cells that give life to those cells are ly­ing dor­mant. And Fre­quen­cy plans to de­vel­op a ther­a­py that can spur them back in­to busi­ness.

That ap­proach — like jump start­ing a dead bat­tery to get a car back on the road — gave birth to a plat­form coined prog­en­i­tor cell ac­ti­va­tion (PCA), and a strat­e­gy to de­vel­op small mol­e­cules to re­store hear­ing. Fre­quen­cy be­lieves the plat­form has the kind of ver­sa­til­i­ty that can take it in­to oth­er dis­ease fields, such as reti­nal dis­eases, skin ail­ments or di­a­betes.

Loose and Lucchi­no, who both worked on Sem­prus Bio­Sciences, one of more than 30 Langer-in­spired biotech star­tups which was sold in 2012, are part of a 12-mem­ber team that’s do­ing the pre­clin­i­cal work. They plan to jump in­to hu­man stud­ies in about 18 months. And they’re ea­ger to prove that re­viv­ing dor­mant stem cells could be a much more ef­fec­tive and ef­fi­cient ap­proach than the more com­plex sci­ence be­hind stem cell ther­a­peu­tics.

This isn’t your clas­sic biotech start­up mod­el, ex­plains Chair­man Marc Co­hen, an­oth­er well-con­nect­ed biotech play­er drawn by Fre­quen­cy’s po­ten­tial. Co­hen had been chair­man at Acety­lon be­fore Cel­gene ac­quired the com­pa­ny, and is chair­man at C4, which launched with a $73 mil­lion round last year. He and his broth­er run Co­bro Ven­tures. And in­stead of round­ing up ven­ture back­ers, they’ve been as­sem­bling the team and start­ing the work with some non­tra­di­tion­al back­ing.

“We have brought to­geth­er a group of an­gels, or su­per an­gels, I worked with in the past to pro­vide the ini­tial fund­ing of the com­pa­ny,” says Co­hen. “That’s a group of peo­ple with a sim­i­lar vi­sion, and we’re look­ing for­ward to ad­vance this, get it in­to the clin­ic.”

“What’s nice about this space is that the end­points are crys­tal clear,” says Loose. “You don’t need ex­treme­ly long-term out­comes stud­ies. That’s a ben­e­fit.”

Fre­quen­cy is ex­pand­ing, and it’s al­so mov­ing away from Kendall Square and in­to a new fa­cil­i­ty Alexan­dria built in Woburn. But while it may be a bit fur­ther from the cen­ter of the biotech hub, you can ex­pect the biotech to turn up the vol­ume on its next stage of de­vel­op­ment.

You’re like­ly to hear them loud and clear.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Uğur Şahin, BioNTech CEO (ddp images/Sipa USA/Sipa via AP Images)

BioN­Tech bets on dif­fi­cult STING field via small mol­e­cule pact with a Pol­ish biotech

BioNTech is beefing up its relatively thin small molecule pipeline by adding weight to a clinically difficult corner of oncology R&D: STING agonists. To do so, BioNTech is teaming up with a 15-year-old Polish biotech and doling out €40 million, about $41.5 million, to start.

The deal is broken into two parts: First, BioNTech obtains an exclusive global license to develop and market Ryvu Therapeutics’ STING agonist portfolio as small molecules, whether alone or in combination with other agents.

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Catal­ent to cut about 200 jobs in Mary­land and Texas

Contract manufacturing company Catalent is cutting about 200 jobs in Maryland and Texas, according to WARN notices, trimming back some of its pandemic-era expansion.

The company will cut 77 jobs by Jan. 15 of next year at a cell therapy facility in Webster, TX, just outside of Houston. In Maryland, the company is reducing staff at two locations, with 82 jobs being eliminated at Catalent’s facility in Gaithersburg, and 53 in Rockville. The layoffs go into effect at those locations on Jan. 14.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

iECURE CEO Joe Truitt and founder Jim Wilson

Jim Wil­son biotech iECURE gets fresh $65M to push pe­di­atric liv­er dis­ease gene ther­a­py in­to the clin­ic

Jim Wilson-founded biotech iECURE has wrapped a $65M Series A extension round to get its lead candidate — a gene replacement therapy for a rare inherited liver disease known as ornithine transcarbamylase deficiency, or OTC — into the clinic.

This round was co-led by Novo Holdings and LYFE Capital, followed by initial investors Versant and OrbiMed as well. In September 2021, iECURE raised a $50 million Series A led by the latter two. The new cash infusion will get iECURE through an initial in-human trial, which CEO Joe Truitt told Endpoints News iECURE hopes to read out in 2024.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Tim Walbert, Horizon Therapeutics CEO (via YouTube)

Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

Amgen, J&J’s Janssen and Sanofi are all in talks to acquire Horizon Therapeutics, the rare disease biotech disclosed late Tuesday.

Horizon confirmed “highly preliminary discussions” with those companies regarding a potential buyout offer after the Wall Street Journal reported takeover interest.

Although the company — which commands a market cap of close to $18 billion — emphasized that “there can be no certainty that any offer will be made for the Company,” shares $HZNP still surged 31% in after-hours trading to near $103, bringing it to the point where it started the year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

John Carroll with David Chang, Allogene CEO (Credit: Jeff Rumans Photography)

Al­lo­gene takes the stage in New York to go deep on its off-the-shelf cell ther­a­pies — de­clar­ing a first for sol­id tu­mors

NEW YORK — In most cases, a biotech like Allogene would wait until the next big science conference to offer its latest series of snapshots of its data. But most biotechs aren’t like Allogene, where the veteran leaders from Kite garnered a substantial number of kudos over the years for their in-depth reviews of the company’s progress.

So on Tuesday, the leaders at Allogene converged on Manhattan once again to give a detailed breakdown of their latest steps forward, looking to stay out front in the busy off-the-shelf cell therapy arena, keep a clean bill of health on the safety front and prove that they can not only match the autologous pioneers they helped create but make the all-important leap into solid tumors. It’s another step forward in a journey that has a long way to go before even the first big regulatory finish lines appear on the track. But for CEO David Chang, who spent some time with me running through the data ahead of the Tuesday session, it all amounts to forward momentum toward the desired goal.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.